Krystal Biotech KRYS

$ 163.39 1.59%

Quarterly report 2024-Q3
added 11-04-2024

Krystal Biotech Balance Sheet 2011-2024 | KRYS

Annual Balance Sheet Krystal Biotech

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-350 M	-153 M	-333 M	-	-184 M	-104 M	-49.6 M	-80 K	-	-	-	-	-
Long Term Debt	6.62 M	7.37 M	6.98 M	-	-	-	-	1.84 M	-	-	-	-	-
Long Term Debt Current	1.47 M	1.56 M	1.04 M	5.11 M	480 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	2.78 M	294 K	-	1.85 M	-	-	-	-	-
Total Current Liabilities	33.1 M	28.8 M	25.7 M	15.5 M	3.33 M	-	640 K	-	-	-	-	-	-
Total Liabilities	39.7 M	36.2 M	32.7 M	18.8 M	6.11 M	2.89 M	640 K	1.89 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-270 M	-281 M	-141 M	-71.2 M	-39 M	-20 M	-9.07 M	-1.15 M	-	-	-	-	-
Total Assets	818 M	558 M	626 M	311 M	209 M	116 M	50.1 M	2.18 M	-	-	-	-	-
Cash and Cash Equivalents	358 M	162 M	341 M	268 M	188 M	104 M	49.6 M	1.92 M	-	-	-	-	-
Book Value	779 M	522 M	594 M	292 M	203 M	113 M	49.5 M	289 K	-	-	-	-	-
Total Shareholders Equity	779 M	522 M	594 M	292 M	203 M	113 M	49.5 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Krystal Biotech

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	6.18 M	6.33 M	6.46 M	6.62 M	6.82 M	7.01 M	7.2 M	7.37 M	7.58 M	7.72 M	7.88 M	6.98 M	7.08 M	6.9 M	3.22 M	3.31 M	3.31 M	3.31 M	3.31 M	2.78 M	2.78 M	2.78 M	2.78 M	-	-	-	-	-	-	4.25 M	4.25 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	96.5 M	78.8 M	54.1 M	39.7 M	34.4 M	30.9 M	42.3 M	36.2 M	35.6 M	42.1 M	68.3 M	32.7 M	42.9 M	25 M	12.4 M	18.8 M	18.8 M	18.8 M	18.8 M	6.11 M	6.11 M	6.11 M	6.11 M	2.89 M	2.89 M	2.89 M	2.89 M	640 K	2.48 M	640 K	640 K	1.89 M	1.89 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-226 M	-253 M	-269 M	-270 M	-279 M	-359 M	-326 M	-281 M	-249 M	-219 M	-191 M	-141 M	-119 M	-103 M	-87 M	-71.2 M	-71.2 M	-71.2 M	-71.2 M	-39 M	-39 M	-39 M	-39 M	-20 M	-20 M	-20 M	-20 M	-9.07 M	-7.68 M	-9.07 M	-9.07 M	-1.15 M	-1.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	982 M	918 M	853 M	818 M	790 M	684 M	532 M	558 M	576 M	601 M	617 M	626 M	451 M	444 M	443 M	311 M	311 M	311 M	311 M	209 M	209 M	209 M	209 M	116 M	116 M	116 M	116 M	50.1 M	52.7 M	50.1 M	50.1 M	2.18 M	2.18 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	374 M	346 M	359 M	358 M	373 M	276 M	141 M	162 M	186 M	219 M	269 M	341 M	287 M	330 M	402 M	268 M	268 M	268 M	268 M	188 M	188 M	188 M	188 M	104 M	104 M	104 M	104 M	49.6 M	49.6 M	49.6 M	49.6 M	1.92 M	1.92 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	886 M	839 M	799 M	779 M	756 M	653 M	490 M	522 M	541 M	559 M	549 M	594 M	408 M	419 M	431 M	292 M	292 M	292 M	292 M	203 M	203 M	203 M	203 M	113 M	113 M	113 M	113 M	49.5 M	50.2 M	49.5 M	49.5 M	289 K	289 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	886 M	839 M	799 M	779 M	756 M	653 M	490 M	522 M	541 M	559 M	549 M	594 M	408 M	419 M	431 M	292 M	292 M	292 M	292 M	203 M	203 M	203 M	203 M	113 M	113 M	113 M	113 M	49.5 M	49.5 M	49.5 M	49.5 M	289 K	289 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency